Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth

NodeGuardian · 2026-03-19T00:13:51+00:00

Strata Critical Medical (SRTA) is rated "Buy," with a projected 30-35% upside in 12-24 months due to its transformation into a medical logistics provider, robust FY25 results, and an aggressive acquisition strategy. It trades at a discount to peers, indicating re-rating potential.

NodeGuardian

2026-03-19 00:13:51

Abstract generation in progress

Strata Critical Medical (SRTA) is rated as a “Buy” with a 12-24 month horizon, anticipating 30-35% upside due to its attractive valuation and transformation into a pure-play medical logistics provider. The company’s robust FY25 results, margin expansion, and an aggressive acquisition strategy are expected to drive sustained revenue and EBITDA growth. SRTA trades at a significant EV/EBITDA discount to peers, suggesting strong re-rating potential.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.